Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

TVF Communications

- PMLiVE

AstraZeneca expands rare disease pipeline with $1.05bn Amolyt Pharma acquisition

The deal gives the company access to a late-stage candidate being evaluated for hypoparathyroidism

- PMLiVE

Pfizer’s Adcetris combination shows promise in phase 3 large B-cell lymphoma study

The aggressive blood cancer affects more than 25,000 people in the US every year

regeneron headquarters

Regeneron’s Praluent receives FDA approval for paediatric patients with genetic high cholesterol

Patients aged eight year or older with heterozygous familial hypercholesterolaemia will be eligible to receive the treatment

- PMLiVE

Dermavant reports positive late-stage results for Vtama cream in atopic dermatitis

The inflammatory skin disease affects up to 10% of adults and 20% of children worldwide

- PMLiVE

How is the vaccine reimbursement environment changing?

By Claire Woon

AMICULUM

- PMLiVE

Transforming San Diego for AAD 2024

The 2024 meeting of the American Academy of Dermatology has wrapped up, and Medscape has returned from a series of successful days at their booth, symposia, and offsite event. To...

Medscape Education Global

- PMLiVE

Almirall gains rights to Eloxx’s rare dermatological disease asset in deal worth over $470m

ZKN-013 is designed to overcome nonsense mutations in rare skin diseases such as junctional epidermolysis bullosa

Daiichi Sankyo logo

Daiichi Sankyo’s Vanflyta approved by MHRA to treat acute myeloid leukaemia

The blood cancer affects approximately 3,100 people in the UK annually

- PMLiVE

Eli Lilly shares positive late-stage results for lebrikizumab in atopic dermatitis

The study evaluated lebrikizumab in patients with moderate-to-severe AD and darker skin tones

- PMLiVE

Incyte’s JAK inhibitor cream Opzelura shows promise in hidradenitis suppurativa

The treatment already holds approvals in non-segmental vitiligo and atopic dermatitis

- PMLiVE

Ensuring a seamless transition from design to development: Strategies for successful collaboration

When designing digital products and services, the process of transitioning from design to development plays a critical role in bringing concepts to life. Our Design Lead, Edward Hart, explains why...

Graphite Digital

- PMLiVE

Pfizer’s Velsipity receives MHRA and NICE authorisations to treat ulcerative colitis

The immune-mediated inflammatory bowel disease affects approximately 300,000 people in the UK

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links